β-blockade: benefits beyond blood pressure reduction?
作者信息
Rosendorff Clive
机构信息
From the Mount Sinai School of Medicine, New York, NY;1 and the James J. Peters VA Medical Center, Bronx, NY 2.
出版信息
J Clin Hypertens (Greenwich). 2012 Feb;14(2):69-70. doi: 10.1111/j.1751-7176.2011.00562.x. Epub 2011 Nov 15.
Abstract
摘要
相似文献
1
β-blockade: benefits beyond blood pressure reduction?β受体阻滞剂：降压之外还有其他益处？
J Clin Hypertens (Greenwich). 2012 Feb;14(2):69-70. doi: 10.1111/j.1751-7176.2011.00562.x. Epub 2011 Nov 15.
2
β-blockade: benefits beyond blood pressure reduction?β受体阻滞剂：降压之外的益处？
J Clin Hypertens (Greenwich). 2012 Feb;14(2):112-120. doi: 10.1111/j.1751-7176.2011.00553.x. Epub 2011 Nov 11.
3
Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators.使用肾上腺素能β受体阻滞剂和血管扩张剂进行抗高血压治疗。
Eur J Clin Pharmacol. 1972 Jun;4(3):177-81. doi: 10.1007/BF00561142.
4
Vasodilator administration in the presence of beta-adrenergic blockade.
Circulation. 1976 Jun;53(6):985-8. doi: 10.1161/01.cir.53.6.985.
5
[Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension].
MMW Fortschr Med. 2003 Oct 2;145(40):57.
6
[Role of urapidil in the treatment of arterial hypertension].
Kardiologiia. 1992 Apr;32(4):99-111.
7
An assessment of beta-adrenoceptor blockade in man by SK & F 92657, a new drug with combined vasodilator and beta-adrenoceptor blocking actions, and comparison with propranolol [proceedings].用兼具血管舒张和β-肾上腺素能受体阻断作用的新药SK&F 92657对人体β-肾上腺素能受体阻断作用的评估，并与普萘洛尔作比较[会议论文集]
Br J Clin Pharmacol. 1980 Mar;9(3):300P-301P. doi: 10.1111/j.1365-2125.1980.tb04858.x.
8
Effects of beta-adrenoceptor blocking agents on haemodynamic parameters.β-肾上腺素能受体阻断剂对血流动力学参数的影响。
Acta Med Scand Suppl. 1977;606:49-54. doi: 10.1111/j.0954-6820.1977.tb18029.x.
9
Serial hemodynamic monitoring to guide treatment of maternal hypertension leads to reduction in severe hypertension.连续血流动力学监测以指导孕产妇高血压的治疗可降低重度高血压的发生率。
Ultrasound Obstet Gynecol. 2017 Jan;49(1):95-103. doi: 10.1002/uog.17341.
10
Pharmacodynamic profile of carvedilol.卡维地洛的药效学特征。
Cardiology. 1993;82 Suppl 3:19-23. doi: 10.1159/000175939.
本文引用的文献
1
β-blockade: benefits beyond blood pressure reduction?β受体阻滞剂：降压之外的益处？
J Clin Hypertens (Greenwich). 2012 Feb;14(2):112-120. doi: 10.1111/j.1751-7176.2011.00553.x. Epub 2011 Nov 11.
2
Pulmonary effects of nebivolol.
Ther Adv Cardiovasc Dis. 2009 Aug;3(4):329-34. doi: 10.1177/1753944709339968.
3
Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study.β受体阻滞剂、血管紧张素转换酶抑制剂和钙通道阻滞剂治疗与骨折风险降低相关：一项全国性病例对照研究。
J Hypertens. 2006 Mar;24(3):581-9. doi: 10.1097/01.hjh.0000203845.26690.cb.
4
Cardioselective beta-blockers for chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病的心脏选择性β受体阻滞剂。
Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD003566. doi: 10.1002/14651858.CD003566.pub2.
5
Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.奈必洛尔、布新洛尔、美托洛尔和卡维地洛在人体心肌中无内在拟交感活性。
Br J Pharmacol. 2001 Aug;133(8):1330-8. doi: 10.1038/sj.bjp.0704188.
Zotero 插件